Iron Uptake and Mucormycosis Pathogenesis
Iron Uptake and Mucormycosis Pathogenesis
批准号:
7556321
负责人:
ASHRAF S. IBRAHIM
金额:
$26.94万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-02-01 至 2011-01-31
关键词:
AffectAffinityAgingAngioinvasionAnimal ModelAnimalsAntifungal TherapyBiological AssayBlood VesselsCell LineCellsChelating AgentsClinicalComplementDebridementDevelopmentDiabetes MellitusDiabetic KetoacidosisDiabetic mouseDiseaseDown-RegulationElementsEndothelial CellsEnvironmentFunctional disorderGenerationsGenesHematogenousHistologyHost DefenseImmune responseImmunocompromised HostIn VitroIncidenceInfectionInvadedInvestigationIronIron OverloadLifeMalignant NeoplasmsMediatingMethodsModelingMucormycosisMusNeutropeniaOperative Surgical ProceduresOrgan TransplantationOrganismOryzaPathogenesisPathogenicityPatientsPenetrationPhagocytesPhagocytosisPharmaceutical PreparationsPopulationPredispositionPrevalenceProcessProductionReportingResearch PersonnelRhizopusRiskRisk FactorsRoleSerumSite-Directed MutagenesisSourceSteroidsTechniquesTestingTimeToxic effectUnited StatesVirulencecell injuryclinically relevantcytokinefungusgenetic manipulationin vivoin vivo Modeliron metabolismmortalitymutantneutrophilnon-diabeticnovelpermeasepreventprocess optimizationprogramsreactive oxygen intermediatereceptorresponsetissue tropismuptake
中文摘要
毛霉菌病是一种危及生命的感染,发生在糖尿病患者的免疫功能低下,
酮症酸中毒、中性粒细胞减少症、类固醇使用和/或血清铁增加。由于风险的上升
由于这些因素,毛霉菌病的发病率急剧增加(根据一项研究,15年内增加了1300
来源)。尽管进行了毁容手术和积极的抗真菌治疗,
仍> 50%,在播散性疾病患者中接近100%。显然,新的战略
毛霉菌病的防治是迫切需要的。
毛霉菌病最常见的致病菌--毛霉根霉感染的临床特征包括:
血清铁增加的患者的独特易感性,生物体侵入的倾向,
血管和吞噬功能缺陷,我们假设这是,至少部分,铁的结果
毒性这些临床特征强调了铁代谢的关键作用,以及与铁代谢的相互作用。
内皮细胞内衬血管,在有机体的毒力策略。我们发现R.米
在体外损伤内皮细胞,并且该过程依赖于铁。此外,我们还克隆了R。
高亲和力铁通透酶(rFTR 1),其从铁耗尽的环境中清除铁,
在主机中找到。最后,我们开发了临床相关的糖尿病酮症酸中毒感染模型,
小鼠我们假设铁的摄取,特别是rFTR 1,是R。引起感染。
为了验证这一假设,我们建议:1)表征铁调节R的机制。-
诱导内皮细胞损伤; 2)构建同基因rFTR无效突变体及其相应的rFTR 1
互补菌株jn R.通过定点突变对稻进行诱变; 3)比较稻的致病性
在我们的体外和体内模型中,
阐明铁在调节宿主对R. - 是的
实现这些具体目标将确定影响建立的中心要素的作用,
和毛霉菌病的进展,因为它与铁的吸收有关。最后,一个上级的理解
毛霉菌病的发病机理将使得能够开发用于该疾病的新疗法。完成
这项研究将使阻断R的治疗方法成为可能。铁的吸收。
英文摘要
Mucormycosis is a life-threatening infection that occurs in patients immunocompromised by diabetic
ketoacidosis, neutropenia, steroid use, and/or increased serum iron. Because of the rising prevalence of risk
factors, the incidence of mucormycosis has dramatically increased (1300% over 15 years according to one
source). Despite disfiguring surgery and aggressive antifungal therapy, the mortality of mucormycosis
remains >50%, and approaches 100% in patients with disseminated disease. Clearly new strategies to
prevent and treat mucormycosis are urgently needed.
Clinical hallmarks of infection by Rhizopus oryzae, the most common cause of mucormycosis, include the
unique susceptibility of patients with increased available serum iron, the propensity of the organism to invade
blood vessels, and defective phagocytic function, which we hypothesize to be, at least in part, a result of iron
toxicity. These clinical hallmarks underscore the critical role of iron metabolism, as well as interactions with
endothelial cells lining blood vessels, in the organism's virulence strategy. We have found that R. oryzae
damages endothelial cells in vitro and this process is dependent on iron. Additionally, we have cloned the R.
oryzae high affinity iron permease (rFTR1) which scavenges iron from iron-depleted environments such as is
found in the host. Finally we have developed clinically relevant models of infection in diabetic ketoacidotic
mice. We hypothesize that iron uptake, and specifically rFTR1, is essential for R. oryzae to cause infection.
To test this hypothesis, we propose to: 1) characterize the mechanism(s) by which iron regulates R. oryzae-
induced endothelial cell injury; 2) construct an isogenic rftrl null mutant and its corresponding rFTR1
complemented strain jn R. oryzae by site directed mutagenesis; 3) compare the pathogenicity of the
generated rftrl to that of the wild-type and rFTR1 complemented strains in our in vitro and in vivo models of
infection; and 4) elucidate the role of iron in regulating the innate host response to R. oryzae.
Accomplishing these specific aims will define the role of the central elements affecting the establishment
and progression of mucormycosis as it relates to iron uptake. Ultimately, a superior understanding of the
pathogenesis of mucormycosis will enable development of novel therapies for this disease. Completion of
the proposed studies will enable investigation of treatments that block R. oryzae uptake of iron.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10338103
-
项目类别:
-
资助金额:$104.73万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens Supplement
-
批准号:10564958
-
项目类别:
-
资助金额:$3.84万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10728900
-
项目类别:
-
资助金额:$8.31万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10535474
-
项目类别:
-
资助金额:$115.18万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10084265
-
项目类别:
-
资助金额:$102.25万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Humanized monoclonal antibodies to treat mucormycosis
-
批准号:9759762
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2018
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Humanized monoclonal antibodies to treat mucormycosis
-
批准号:10599750
-
项目类别:
-
资助金额:$98.79万
-
财政年份:2018
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections
-
批准号:9089918
-
项目类别:
-
资助金额:$19.71万
-
财政年份:2015
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections
-
批准号:9488843
-
项目类别:
-
资助金额:$45.71万
-
财政年份:2015
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections
-
批准号:9755205
-
项目类别:
-
资助金额:$48.15万
-
财政年份:2015
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
An Ftr1 vaccine to abrogate mucormycosis
-
批准号:8020985
-
项目类别:
-
资助金额:$20.52万
-
财政年份:2010
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
An Ftr1 vaccine to abrogate mucormycosis
-
批准号:7896157
-
项目类别:
-
资助金额:$18.12万
-
财政年份:2010
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS
-
批准号:8174480
-
项目类别:
-
资助金额:$0.41万
-
财政年份:2009
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS
-
批准号:7952233
-
项目类别:
-
资助金额:$0.63万
-
财政年份:2008
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS
-
批准号:7606192
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2007
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment
-
批准号:10666383
-
项目类别:
-
资助金额:$55.48万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Novel Antifungal Strategies for Lethal Mucormycosis
-
批准号:7268002
-
项目类别:
-
资助金额:$19.37万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Iron Uptake and Mucormycosis Pathogenesis
-
批准号:8685093
-
项目类别:
-
资助金额:$35.29万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Iron Uptake and Mucormycosis Pathogenesis
-
批准号:7383193
-
项目类别:
-
资助金额:$26.71万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Iron Uptake and Mucormycosis Pathogenesis
-
批准号:8889496
-
项目类别:
-
资助金额:$35.49万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
海外基金